Effect of preoperative Silodosin on facilitating access sheath placement in retrograde intrarenal surgery. A randomized controlled studys.

IF 1.3 Q3 UROLOGY & NEPHROLOGY

Arab Journal of Urology Pub Date : 2024-10-10 eCollection Date: 2025-01-01 DOI:10.1080/20905998.2024.2414134

Ahmed Higazy, Mohamed Samir, Ahmed AbdelGhani, A M Tawfeek, Ahmed Radwan

{"title":"Effect of preoperative Silodosin on facilitating access sheath placement in retrograde intrarenal surgery. A randomized controlled studys.","authors":"Ahmed Higazy, Mohamed Samir, Ahmed AbdelGhani, A M Tawfeek, Ahmed Radwan","doi":"10.1080/20905998.2024.2414134","DOIUrl":null,"url":null,"abstract":"Introduction: to evaluate the effect of preoperative Silodosin on ureteric dilatation to facilitate ureteral access sheath (UAS) placement and reduction of ureteral wall injury in retrograde intrarenal surgery (RIRS).Methods: one hundred and twenty patients with renal or ureteric stones were randomly allocated into 2 equal groups. Group A represents patients who received a 7-day preoperative single dose Silodosin before RIRS while Group B represents patients who received a placebo for the same regimen. Our primary outcome was to assess the success rate of (UAS) placement. Our secondary outcomes were to evaluate the perioperative complication rate, stone-free rate, hospital stay, and cost analysis.Results: In our study, Silodosin showed a higher success rate for (UAS) insertion compared to placebo with a statistically significant difference (p-value = 0.04). Spontaneous UAS insertion in the Silodosin group was 58.3%, which was increased with active ureteric dilatation to 98.3%. Preoperative Silodosin led to less postoperative pain and analgesics requirements without impacting postoperative hospital stay or stone-free rate. There was less ureteric injury incidence in the Silodosin group compared to placebo with a statistically significant difference (p-value = 0.002).Conclusion: Preoperative Silodosin facilitates UAS insertion with a protective role against ureteric injury compared to placebo.","PeriodicalId":8113,"journal":{"name":"Arab Journal of Urology","volume":"23 2","pages":"117-123"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963177/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arab Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20905998.2024.2414134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: to evaluate the effect of preoperative Silodosin on ureteric dilatation to facilitate ureteral access sheath (UAS) placement and reduction of ureteral wall injury in retrograde intrarenal surgery (RIRS).

Methods: one hundred and twenty patients with renal or ureteric stones were randomly allocated into 2 equal groups. Group A represents patients who received a 7-day preoperative single dose Silodosin before RIRS while Group B represents patients who received a placebo for the same regimen. Our primary outcome was to assess the success rate of (UAS) placement. Our secondary outcomes were to evaluate the perioperative complication rate, stone-free rate, hospital stay, and cost analysis.

Results: In our study, Silodosin showed a higher success rate for (UAS) insertion compared to placebo with a statistically significant difference (p-value = 0.04). Spontaneous UAS insertion in the Silodosin group was 58.3%, which was increased with active ureteric dilatation to 98.3%. Preoperative Silodosin led to less postoperative pain and analgesics requirements without impacting postoperative hospital stay or stone-free rate. There was less ureteric injury incidence in the Silodosin group compared to placebo with a statistically significant difference (p-value = 0.002).

Conclusion: Preoperative Silodosin facilitates UAS insertion with a protective role against ureteric injury compared to placebo.

查看原文本刊更多论文

术前服用西洛多辛对逆行肾内手术入路鞘置入的促进作用。随机对照研究

简介：目的：评估在逆行肾内手术（RIRS）中，术前服用西洛多辛对输尿管扩张以促进输尿管通道鞘（UAS）置入和减少输尿管壁损伤的影响。方法：将120名肾结石或输尿管结石患者随机分配到两个相同的组别。A 组代表在逆行肾内手术前接受为期 7 天的术前单剂西洛多辛治疗的患者，而 B 组代表接受安慰剂治疗的患者。我们的主要结果是评估（UAS）置入的成功率。我们的次要结果是评估围手术期并发症发生率、无结石率、住院时间和成本分析：在我们的研究中，与安慰剂相比，西洛多辛显示出更高的（UAS）置入成功率，差异有统计学意义（p 值 = 0.04）。西洛多辛组的 UAS 自发插入率为 58.3%，随着输尿管的积极扩张，这一比例上升到 98.3%。术前服用西洛多辛减少了术后疼痛和镇痛药的需求，但不影响术后住院时间或无结石率。西洛多辛组的输尿管损伤发生率低于安慰剂组，差异有统计学意义（P值=0.002）：结论：与安慰剂相比，西洛多辛有助于术前插入 UAS，对输尿管损伤具有保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arab Journal of Urology UROLOGY & NEPHROLOGY-

CiteScore

2.80

自引率

0.00%

发文量

期刊介绍： The Arab Journal of Urology is a peer-reviewed journal that strives to provide a high standard of research and clinical material to the widest possible urological community worldwide. The journal encompasses all aspects of urology including: urological oncology, urological reconstructive surgery, urodynamics, female urology, pediatric urology, endourology, transplantation, erectile dysfunction, and urinary infections and inflammations. The journal provides reviews, original articles, editorials, surgical techniques, cases reports and correspondence. Urologists, oncologists, pathologists, radiologists and scientists are invited to submit their contributions to make the Arab Journal of Urology a viable international forum for the practical, timely and state-of-the-art clinical urology and basic urological research.